Venture Prepares for Structured Acquisitions
This article was originally published in Start Up
Executive SummaryWith Big Pharma content to sit on the sidelines and wait as biotech company valuations continue their fall, the M&A activity that does take place is likely to place a premium on hedging risk. And, say venture investors, that means structured acquisitions of biotech firms are likely to increase as pharmaceutical acquirers gain more leverage over cash-strapped firms in deal negotiations.
You may also be interested in...
H.I.G. Capital announced the closing of BioVentures II, a diversified life science venture fund focusing on drugs, medical devices, and diagnostics.